Sweaty feet in adolescents

• Verfasst von: Bernhard, Matthias K. [VerfasserIn]
• Verfasst von: Krause, Matthias [VerfasserIn]
• Verfasst von: Syrbe, Steffen [VerfasserIn]
• Titel: Sweaty feet in adolescents
• Titelzusatz: early use of botulinum type A toxin in juvenile plantar hyperhidrosis
• Verf.angabe: Matthias K. Bernhard, Matthias Krause, Steffen Syrbe
• E-Jahr: 2018
• Jahr: 04 September 2018
• Umfang: 3 S.
• Fussnoten: Gesehen am 31.07.2019
• Titel Quelle: Enthalten in: Pediatric dermatology
• Ort Quelle: Oxford [u.a.] : Wiley-Blackwell, 1983
• Jahr Quelle: 2018
• Band/Heft Quelle: 35(2018), 6, Seite 784-786
• ISSN Quelle: 1525-1470
• DOI: doi:10.1111/pde.13628
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: adolescents
• Sach-SW: anesthesia
• Sach-SW: botulinum toxin
• Sach-SW: hyperhidrosis
• K10plus-PPN: 1670318176

Abstract

Background/Objectives Plantar hyperhidrosis can have severe social effects on children and adolescents. Therapeutic options include antiperspirants and surgical interventions (eg, sympathectomy). Botulinum type A toxin is approved for axillary hyperhidrosis in adults only. The aim of the study was the determination of effect and safety of botulinum type A toxin in plantar hyperhidrosis in juvenile patients. Methods Children and adolescents with idiopathic focal plantar hyperhidrosis were treated with 50-100 U of botulinum type A toxin per sole. Local anesthesia was provided using topical eutectic mixture of local anesthetics cream and ice, in combination with midazolam as an anxiolytic. Results Fifteen patients (aged 12-17) were included in the study. Best results were achieved with a dose of 75-100 U of botulinum type A toxin per sole. Two patients did not benefit from the therapy, and 11 (73%) were satisfied with the results. Nine patients (60%) experienced pain at the injection site for a maximum duration of 3 days. One patient reported transient focal weakness for 4 weeks. Conclusion Botulinum type A toxin seems to be a safe secondary treatment option for plantar hyperhidrosis in adolescents aged 12 and older. A dose of 75-100 U per sole resulted in a good therapeutic effect of variable duration in most patients. There were no severe side effects.